Xenon Pharmaceuticals Inc.
XENEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Xenon Pharmaceuticals Inc. (XENE) is listed under Biotechnology. At a $5.06B market cap, Xenon Pharmaceuticals Inc. ranks as a mid-cap company within healthcare. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
Market Cap
$5.06B
Beta
0.65
P/E (TTM)
—
P/E (Fwd)
-10.44
EPS (TTM)
$-4.70
EPS (Fwd)
$-5.01
ROE
-37.5%
ROA
-24.2%
Cash
$1.09B
Total Debt
$7.5M
Free CF
-$186.3M
52W Change
71.7%
Annual Financials
Cash vs Debt
Xenon Pharmaceuticals Inc. holds $1.09B in cash against $7.5M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$186.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -37.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $9.4M (2022) to $7.5M (2025), a 21% decline worth watching.
The relatively low beta of 0.65 suggests XENE is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, XENE has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing XENE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.